Octagon Capital Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Octagon Capital Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-204,500	Closed	-$1.24M	–	43
2023 Q3	$1.24M	Sell	204,500 -72,500	-26%	-$594K	0.19%	36
2023 Q2	$2.15M	Buy	+277,000	New	+$1.57M	0.3%	33

Other funds holding ORIC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Octagon Capital Advisors's ORIC Position: Q4 2023 in Review

Octagon Capital Advisors sold out of Oric Pharmaceuticals (ORIC) in Q4 2023, closing a stake of 204,500 shares — an estimated $1.24M sold.

Octagon Capital Advisors first reported a position in ORIC in Q2 2023 and held it in 2 quarters. The position peaked at $2.15M in Q2 2023. 92 funds tracked by Wall St. Rank hold ORIC as of Q4 2023.

Octagon Capital Advisors reported no remaining Oric Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Octagon Capital Advisors sold 204,500 Oric Pharmaceuticals shares in Q4 2023, an estimated $1.24M.
Octagon Capital Advisors first reported a position in Oric Pharmaceuticals in Q2 2023 and held it in 2 quarters.
Octagon Capital Advisors's Oric Pharmaceuticals position peaked at $2.15M in Q2 2023.
92 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.